Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Juan David Assaf"'
Autor:
Susana Cedres, Augusto Valdivia, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Juan David Assaf-Pastrana, Enriqueta Felip, Pilar Garrido
Publikováno v:
Cancers, Vol 15, Iss 24, p 5787 (2023)
Malignant pleural mesothelioma (MPM) is a locally aggressive disease related to asbestos exposure with a median survival for untreated patients of 4–8 months. The combination of chemotherapy based on platinum and antifolate is the standard treatmen
Externí odkaz:
https://doaj.org/article/e99428daa93e4e52aa9b4984eff5732b
Autor:
Susana Cedres, Garazi Serna, Alberto Gonzalez-Medina, Augusto Valdivia, Juan David Assaf-Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Ilaria Priano, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Victor Navarro, Rodrigo Dienstmann, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip
Publikováno v:
Cancers, Vol 15, Iss 14, p 3611 (2023)
MPM is an aggressive disease with an immunosuppressive tumor microenvironment, and interest in exploring immunotherapy in this disease has been increasing. In the first line of treatment, the combination of nivolumab and ipilimumab demonstrated an im
Externí odkaz:
https://doaj.org/article/fd6d684957804a0eace0d7310936322d
Autor:
Patricia Iranzo, Ana Callejo, Juan David Assaf, Gaspar Molina, Daniel Esteban Lopez, David Garcia-Illescas, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Susana Cedres, Caterina Carbonell, Joan Frigola, Ramon Amat, Enriqueta Felip
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found on the surface of antig
Externí odkaz:
https://doaj.org/article/68096871b81a4586b6908a2820df93e1
Autor:
Ana Callejo, Joan Frigola, Patricia Iranzo, Caterina Carbonell, Nely Diaz, David Marmolejo, Juan David Assaf, Susana Cedrés, Alex Martinez-Marti, Alejandro Navarro, Nuria Pardo, Ramon Amat, Enriqueta Felip
Publikováno v:
Cancers, Vol 13, Iss 13, p 3249 (2021)
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed as
Externí odkaz:
https://doaj.org/article/2ec6ac6246874c77ad48062c0ad988a2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alberto Hernando-Calvo, Oriol Mirallas, David Marmolejo, Omar Saavedra, María Vieito, Juan David Assaf Pastrana, Susana Aguilar, Coro Bescós, Juan Lorente, Jordi Giralt, Sergi Benavente, Jordi Temprana-Salvador, Margarita Alberola, Rodrigo Dienstmann, Elena Garralda, Enriqueta Felip, Guillermo Villacampa, Irene Brana
Publikováno v:
Oral Oncology. 140:106364
Autor:
Laia Garrigós, Santiago Escrivá-de-Romaní, Juan David Assaf, Mafalda Oliveira, Cristina Saura
Publikováno v:
Expert Review of Anticancer Therapy. 20:731-741
Several agents are being developed for advanced HER2-positive breast cancer, such as potent tyrosine kinase inhibitors (TKI) targeting ErbB family receptors, novel antibody-drug conjugates, higher affinity anti-HER2 antibodies, among others. Neratini
Autor:
Susana Cedres, Alex Martinez-Marti, Juan-David Assaf, Caterina Carbonell, D. Marmolejo, Joan Frigola, Rodrigo Dienstmann, N. Pardo, A. Pedrola, Enriqueta Felip, P. Iranzo, Alejandra Rezqallah, Ramon Amat, A. Callejo, Alejandro Navarro
Publikováno v:
Scientia
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Cancer therapy; Mesothelioma Terapia del cáncer; Mesotelioma Teràpia del càncer; Mesotelioma CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8904159c255efe30d7d03382a7686988
https://hdl.handle.net/11351/7550
https://hdl.handle.net/11351/7550
Autor:
Susana Cedres Perez, Garazi Serna, Juan David Assaf Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Carlos Cabrera Galvez, Alberto Gonzalez-Medina, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology. 40:e20595-e20595
e20595 Background: MPM is an aggressive cancer associated with asbestos exposure. Chemotherapy has been a mainstay of therapy and recently immunotherapy has been associated with survival improvements. Chemotherapy and immunotherapy influence the tumo
Autor:
David Humberto Marmolejo Castañeda, Alex Martinez-Marti, Caterina Carbonell, Juan David Assaf Pastrana, Julia Lostes, A. Pedrola, Ramon Amat, N. Pardo, Susana Cedres Perez, Javier Gonzalo, A. Callejo, Rodrigo Dienstmann, Alejandro Navarro, Enriqueta Felip, P. Iranzo, Joan Frigola
Publikováno v:
Journal of Clinical Oncology. 39:e20563-e20563
e20563 Background: MPM is a highly aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy. Histology is a prognostic factor and recently CheckMate 743 trial demonstrated survival benefit of immun